Charles Schwab Investment Management Inc. Grows Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Charles Schwab Investment Management Inc. raised its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 2.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 602,321 shares of the medical device company’s stock after buying an additional 16,258 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.92% of Tandem Diabetes Care worth $21,696,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Brooklyn Investment Group acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $28,000. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $29,000. Jones Financial Companies Lllp boosted its position in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after acquiring an additional 748 shares during the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter.

Tandem Diabetes Care Stock Up 1.8 %

Shares of TNDM opened at $20.06 on Wednesday. The stock has a market capitalization of $1.33 billion, a PE ratio of -10.39 and a beta of 1.45. Tandem Diabetes Care, Inc. has a 1 year low of $17.64 and a 1 year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s 50-day simple moving average is $30.69 and its 200-day simple moving average is $34.21.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wells Fargo & Company reissued an “equal weight” rating and set a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Royal Bank of Canada lowered their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Barclays decreased their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, Morgan Stanley cut shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.38.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.